Srsf1敲低对GT1-7细胞基因表达谱的影响

目的:本研究通过RNA-seq技术分析Srsf1基因表达敲低的GT1-7细胞(knock down, KD)和野生型GT1-7细胞(wide type,WT)的表达谱和可变剪接事件,研究Srsf1敲低对GT1-7细胞基因表达谱的影响。方法:利用实验室现有的Srsf1基因表达敲低的GT1-7细胞(SRSF1-KD)和野生型GT1-7细胞分别抽提RNA,做RNA-seq数据分析,利用r MATS软件分析两株细胞内可变剪接事件的变化,确定Srsf1调控的下游关键基因。结果:结果显示共有875个基因表达存在显著性差异,对这些基因进行KEGG通路分析,发现γ-氨基丁酸能突触、PI3K-Akt信号通路、MAPK信号通路等与性发育相关的通路均受到影响。此外,P53通路也受到Srsf1敲低的影响。利用r MATS软件进行可变剪接事件分析,显示共发生839个可变剪接事件,涉及719个基因,进行KEGG通路分析发现与性发育相关的MAPK信号通路受到影响。结论:成功检测了GT1-7细胞和Srsf1基因敲低的GT1-7细胞表达谱,通过分析基因表达差异以及可变剪接事件,证明了Srsf1对于PI3K-Akt信号通路、MAPK信号通路、γ-氨基丁酸能突触信号通路、p53通路的调控作用,并且这些信号通路提示我们Srsf1可能更多的通过非可变剪接方式影响性发育相关基因的表达,而非可变剪接方式,从而为更深入的性发育研究提供了理论基础。     

利用慢病毒介导的shRNA在GT1-7细胞中敲低Srsf1及其对GnRH、Kiss1的影响

目的:探讨慢病毒介导短发夹RNA(shRNA)敲低丝氨酸/精氨酸富集剪接因子1(Srsf1)基因对小鼠GT1-7细胞中性发育相关基因促性腺激素释放激素(GnRH)、Kiss1的影响。方法:实验分为3组,即空白对照组、阴性对照组及shRNA干扰组。用Srsf1 shRNA慢病毒稳转GT1-7细胞,Real-time PCR和Western blot检测GT1-7细胞中Srsf1在mRNA和蛋白水平的变化,并检测稳转株中GnRH、Kiss1基因的表达情况。结果:慢病毒介导的shRNA成功感染了GT1-7细胞,与空白对照组及阴性对照组相比,shRNA干扰组中Srsf1在mRNA水平降低了45%(P0.001),在蛋白水平敲低了42%(P0.05)。在稳定低表达Srsf1的GT1-7细胞中,GnRH、Kiss1基因在mRNA水平也显著降低(P0.05)。结论:成功的构建了Srsf1基因敲低的细胞株。在GT1-7细胞中敲低Srsf1基因会抑制GnRH、Kiss1基因的表达。     

LIN28A在GT1-7细胞中过表达对性发育相关基因的影响

[目的]在GT1-7细胞过表达LIN28A,研究其与性发育相关基因表达是否存在调控关系; RNA-seq发现LIN28A参与调控性发育的信号通路和基因。[方法]构建LIN28A慢病毒过表达载体,转染GT1-7细胞,Real-Time PCR检测LIN28A和性发育相关基因在mRNA水平表达变化;将过表达LIN28A的GT1-7细胞进行RNA-seq、生物信息学分析、Real-Time PCR验证,找到影响性发育的信号通路和基因。[结果]与对照相比,LIN28A在GT1-7细胞过表达18倍(P <0. 001),KISS1在mRNA水平显著升高(P <0. 01); KEGG分析,LIN28A相关的差异基因在MAPK信号通路差异显著,MAPK通路筛选到多个性发育相关基因(Fgf21、JUN、Cyp1a1、Rasgrp2),Real-Time PCR验证它们在mRNA水平差异显著(P <0. 05)。[结论]成功构建LIN28A慢病毒过表达载体,LIN28A在GT1-7细胞中过表达会促进KISS1的表达,并且LIN28A可能通过MAPK通路调控性发育。     

利用基于CRISPR-Cas9 的基因编辑技术对miR-29a在GT1-7 细胞中进 行基因敲除

目的:本文利用CRISPR-Cas9技术在GT1-7细胞中对miR-29a基因进行基因编辑,用于构建miR-29a基因敲除GT1-7细胞模型。方法:通过构建Cas9稳转的GT1-7细胞株并转染sgRNA质粒用于在靶向miR-29a基因区域引发突变。然后构建EGFP与sgRNA共表达质粒并转染Cas9稳转GT1-7细胞,利用流式细胞仪富集表达绿色荧光蛋白的阳性细胞和分选阳性单克隆细胞。最后利用实时荧光定量PCR(realtimefluorescencequantitativePCR)对富集细胞和单克隆细胞进行miR-29a表达量检测。结果:T7E1检测结果显示CRISPR-Cas9系统有效地在miR-29a基因区域引发了突变。荧光定量PCR结果显示,与对照组相比,富集后阳性细胞miR-29a的表达量整体下降了50%左右(P0.05)。此外,通过流式筛选获得了一个纯合miR-29a基因敲除细胞克隆,与对照组相比,其miR-29a的表达量下降了75%左右(P0.05)。结论:本文建立了一种有效编辑GT1-7细胞基因的方法,并采用该方法构建了miR-29a稳定敲除细胞模型。     

Metalloendopeptidase EC3.4.24.15 is constitutively released from the exofacial leaflet of lipid rafts in GT1-7 cells

Metalloendopeptidase EC3.4.24.15 (EP24.15) is a physiologically important neuropeptide-degrading enzyme involved in the metabolism of multiple neuropeptides. The mechanism of release of EP24.15 from neuronal cells is multimodal, being both constitutive and stimulatable. Previous studies have characterized stimulated EP24.15 secretion, yet little is understood concerning constitutive release of the peptidase. Utilizing the mouse hypothalamic neuronal GT1-7 cell line, we demonstrate that EP24.15 exists within lipid rafts in the plasma membrane, and that the enzyme is localized to the exofacial leaflet of lipid rafts. Further, we have found that biotinylated EP24.15 on the extracellular surface is released into the cell media in a fashion similar to constitutive release. In addition, classical and non-classical secretion pathway inhibitors were employed to understand the release of EP24.15 into surrounding cell media. The non-classical secretion inhibitor glyburide, a blocker of ATP-sensitive K+ channels, decreased the amount of constitutively released EP24.15 in cell media of GT1-7 cells. With these data, we conclude that EP24.15 association with lipid rafts on the extracellular surface precedes constitutive release of the peptidase into the extracellular milieu for its action on neuropeptides.     

A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor

Four sets of centrally truncated analogues of neuropeptide Y have been synthesized. In each series the N-terminal part was constant, while the C-terminal segment was systematically varied in length. The C- and N-terminal parts were linked by 6-aminohexanoic acid. The affinity to the Y₁ receptor was investigated on human neuroblastoma cells SK-N-MC. Significant differences were found between the series of peptides as well as within each set. Remarkably, the affinity did not solely depend on the length of the segment, and with increasing numbers of residues the IC₅₀ values were not always decreased. With a given N-terminal segment, only one optimal length of the C-terminal segment was found, which suggests that it is not the amino acids themselves but their 3D arrangement and orientation that is important for high receptor affinity.     

Unexpected high density of neuropeptide Y Y1 receptors in the guinea pig spleen

Receptors for neuropeptide Y (NPY) and peptide YY (PYY) have been extensively characterized in the brain. Less is known about NPY receptor subtypes in the spleen, though it is well established that NPY produces vascular contraction in this tissue. In the present study, we found an unusually high density of Y₁ receptors in the guinea pig spleen. These receptors are localized to the red pulp and exhibit a pharmacology that is consistent with the Y₁ receptor. On the other hand, only very low densities for Y₂ receptors were observed. Therefore, the guinea pig spleen may be a ideal tissue for further study of the role of Y₁ receptors in cardiovascular and immune function.     

二代测序应用于检测GT1-7细胞中KISS1和GnRH启动子的DNA甲基化状态的研究

目的:利用二代测序技术检测GT1-7细胞中KISS1和GnRH基因启动子范围内的甲基化状态,并用金标准的亚硫酸氢盐修饰后的克隆测序作为对照,比较二代测序与金标准克隆测序在研究DNA甲基化检测中的差别。方法:提取GT1-7细胞基因组DNA并进行亚硫酸氢盐处理。进行巢式PCR,将PCR产物进行二代测序。同时采用金标准的亚硫酸氢盐修饰后克隆测序的方法作为对照,对相同批次的PCR产物进行克隆测序。结果:PCR产物二代测序结果表明KISS1和GnRH两个基因的27个CpG甲基化位点信息完整,结果准确。挑取10个克隆进行一代测序结果表明序列无丢失,KISS1和GnRH两个基因的27个CpG甲基化位点信息完整。结论:利用高通量的二代测序技术能够有效的对DNA甲基化的PCR产物进行检测,二代测序和克隆测序都是研究DNA甲基化的有效方法,但前者与克隆测序相比每一个读取序列(reads)都相当于一个单克隆,且二代测序每个区段得到成百上千个reads,因此二代测序结果更加精确。     

Possible involvement of neuropeptide Y Y1 receptors in antidepressant like effect of agmatine in rats

Agmatine and neuropeptide Y (NPY) are widely distributed in central nervous system and critically involved in modulation of depressive behavior in experimental animals. However their mutual interaction, if any, in regulation of depression remain largely unexplored. In the present study we explored the possible interaction between agmatine and neuropeptide Y in regulation of depression like behavior in forced swim test. We found that acute intracerebroventricular (i.c.v.) administration of agmatine (20–40 μg/rat), NPY (5 and 10 μg/rat) and NPY Y1 receptor agonist, [Leu³¹, Pro³⁴]-NPY (0.4 and 0.8 ng/rat) dose dependently decreased immobility time in forced swim test indicating their antidepressant like effects. In combination studies, the antidepressant like effect of agmatine (10 μg/rat) was significantly potentiated by NPY (1 and 5 μg/rat, icv) or [Leu³¹, Pro³⁴]-NPY (0.2 and 0.4 ng/rat, icv) pretreatment. Conversely, pretreatment of animals with NPY Y1 receptor antagonist, BIBP3226 (0.1 ng/rat, i.c.v.) completely blocked the antidepressant like effect of agmatine (20–40 μg/rat) and its synergistic effect with NPY (1 μg/rat, icv) or [Leu³¹, Pro³⁴]-NPY (0.2 ng/rat, icv). The results of the present study showed that, agmatine exerts antidepressant like effects via NPYergic system possibly mediated by the NPY Y1 receptor subtypes and suggest that interaction between agmatine and neuropeptide Y may be relevant to generate the therapeutic strategies for the treatment of depression.     

Analysis of neuropeptide Y-induced feeding: dissociation of Y1 and Y2 receptor effects on natural meal patterns.

To differentiate NPY receptor subtypes, Y₁ and Y₂, in terms of their impact on feeding behavior, the intact molecule NPY(1–36) and the 3 fragments, NPY(2–36), the Y₁ agonist [Leu³¹,Pro³⁴]NPY, and the Y₂ agonist NPY(13–36), were injected (100 pmol/0.3 μl) into the hypothalamic paraventricular nucleus (PVN) of freely feeding rats. A computer-automated data acquisition system was employed in these experiments to permit a detailed analysis of feeding over the 12-h nocturnal cycle, in animals maintained on pure macronutrient diets. The results demonstrate that: 1) NPY(1–36) potentiates feeding behavior, primarily carbohydrate ingestion, by increasing the size and duration of the first meal after injection, rather than by affecting meal number or feeding rate, suggesting that NPY acts through mechanisms of satiety. The potentiation of carbohydrate intake occurs in association with a suppression of protein intake, which is strongest during the second meal after injection and which further increases the proportion of carbohydrate in the diet. No changes in fat ingestion are seen. 2) NPY(2–36), with the N-terminal tyrosine residue deleted, is equally potent to NPY(1–36) in potentiating carbohydrate intake and increasing meal size; however, it is less selective than NPY(1–36), producing an additional, smaller increase in consumption of protein. 3) The stimulatory effect of these peptides on carbohydrate intake and meal size is similarly observed, with somewhat reduced potency, after PVN injection of the selective Y₁ agonist [Leu³¹,Pro³⁴]NPY which, like NPY(1–36), also reduces protein intake. 4) The Y₂ receptor agonist, NPY(13–36), causes a decrease in the ingestion of carbohydrate, a smaller decline in protein intake, and a reduction in meal size. It is proposed that hypothalamic Y₁ receptors mediate the stimulatory effect of NPY on carbohydrate intake and meal size, while Y₂ receptors have the opposite effect of suppressing carbohydrate intake, possibly by altering presynaptic release of monoamines known to influence nutrient ingestion.     

Immunocytochemical localization of neuropeptide Y (NPY) in the human hypothalamus

Summary In order to study the distribution of neuropeptide Y-like immunoreactivity in the human hypothalamus, an immunocytochemical localization of this peptide was performed. Using antibodies developed against synthetic porcine neuropeptide Y (NPY), we have been able to localize immunoreactivity in neuronal cell bodies located exclusively in the infundibular nucleus. Immunostained fibers were found in several regions in the hypothalamus with a high concentration in the periventricular areas. Fibers were also found in the neurovascular zone of the median eminence, the pituitary stalk and the posterior pituitary. These results suggest that immunoreactive material related to porcine NPY is present in the human hypothalamus, with a distribution similar to that observed in the rat.     

Distribution of neuropeptide Y immunoreactivity in human visual cortex and underlying white matter

Immunocytochemical techniques have been used to study neuropeptide Y (NPY) distribution in the human visual cortex (Brodman's areas 17, 18 and 19) NYP cell bodies belong mostly to inhibitory (multipolar and bitufted) but also to excitatory (bipolar and some pyramidal) neuronal types. Their distribution is similar in the three cortical areas studied: 20 to 40% of the NPY perikarya are located in the cortical gray matter, mostly in the deep layers, while the remaining 60 to 80% are located in the underlying white matter. Immunoreactive NPY processes form a rich network of intersecting fibers throughout the entire visual cortex. A superficial plexus (layers I and II) and a deep plexus (deep layer V and layer VI) of NPY fibers are present in areas 17, 18 and 19. In area 17, an additional well developed plexus is present in layers IVb and IVc. These plexuses receive branches from long parallel fibers arising from deep cortical layers or underlying white matter and terminating in superficial layers. Local or extrinsic NPY terminals wind around vessels in the cortex as well as in the white matter, and either penetrate them or form clusters of club endings on their walls. Our results suggest a role for NPY in human visual circuitry and in cortical blood flow regulation.     

Effects of the aqueous extract of Bryothamnion triquetrum on chemical hypoxia and aglycemia-induced damage in GT1-7 mouse hypothalamic immortalized cells

The neuroprotective ability of the aqueous crude extract of Bryothamnion triquetrum (S. G. Gmelin) Howe and its cinnamic acids was studied in GT1-7 cells exposed to the combination of chemical hypoxia (KCN 3 mM) and aglycemia conditions. These ischemia-like conditions provoked acute and delayed cytotoxicity in GT1-7 cells if extended for more than 90 min. The extract was able to protect from the cell death produced by severe (180 min) chemical hypoxia/aglycemia insult, which cannot be related to its glucose content, and also reduced the cytotoxicity and early production of free radicals produced by mild (105 min) insult. Results showed that some of these protective effects of the extract are partially related to the presence of ferulic acid. The data additionally suggest that neuroprotection exerted by the extract is related to its ability to reduce free-radical generation by mechanisms different from the direct scavenging of the radical entities.     

人B7—1和B7—2cDNA的克隆及鉴定

目的：为探索性构建全新型重组人B7－PE40绿脓杆菌外毒素融合蛋白以长期诱导免疫耐受,本研究从急性B淋巴细胞白血病细胞株Raji中隆N－末端分别缺失34和16个氨基酸的人B7－1和B7－2基因胞外区,并构建含此基因的重组质粒。方法：根据B7－1和B7－2基因序列设计合成可增B7－1和B7－2cDNA的特异性引物,用RT－PCR的方法从Raji细胞总RNA中扩增B7－1和B7－2cDNA,并克隆至pGEM－T载体中,经酶切鉴定后再进行序列分析。结果和结论：从Raji细胞中扩增出预期 的624和675bp的B7－1和B7－2cDNA,将其克隆至pGEM-T载体中,分别经EcoRI/HindⅢ和BamHI/SphI双酶切电泳和序列分析确证,为进一步构建人B7－PE40外毒素融合蛋白奠定了基础。     

Autoradiographic reevaluation of the binding properties of 125I-[Leu31,Pro34]peptide YY and 125I-peptide YY3-36 to neuropeptide Y receptor subtypes in rat forebrain

125I-[Leu31,Pro34]peptide YY (PYY) and 125I-PYY3-36, initially described as selective neuropeptide Y Y1 and Y2 receptor ligands, respectively, were recently shown to label also Y4 and Y5 receptors. We used receptor autoradiography to assess whether these ligands can be reliably used to investigate the various neuropeptide Y receptors in rat forebrain. In most of the brain regions examined (in coronal sections at the level of dorsal hippocampus), specific 125I-[Leu31,Pro34]PYY binding was completely inhibited by 1 microM BIBP-3226, a selective Y1 receptor ligand, but unaffected by 10 nM rat pancreatic polypeptide, selectively inhibiting Y4 receptors, suggesting that Y4 receptors are present in negligible numbers compared with Y1 receptors in the areas examined. Significant numbers of BIBP-3226-insensitive 125I-[Leu31,Pro34]PYY binding sites were measured in the CA3 subfield of the hippocampus only, possibly representing Y5 receptors. 125I-PYY3-36 binding was unchanged by 1 microM BIBP-3226, whereas a population of 125I-PYY3-36 binding sites was sensitive to 100 nM [Leu31,Pro34]neuropeptide Y, likely representing Y5 receptors. The possibility of distinguishing between Y2 and Y5 receptors using 125I-PYY3-36 as radioligand was validated by their different regional distribution and their distinct changes 24 h after kainate seizures, i.e., binding to Y5 receptors was selectively decreased in the outer cortex, whereas binding to Y2 receptors was enhanced in the hippocampus. Thus, the use of selective unlabeled compounds is required for distinguishing the various receptor subtypes labeled by 125I-[Leu31,Pro34]PYY and 125I-PYY3-36 in rat brain tissue.     

Neuropeptide Y,enkephalin and noradrenaline coexist in sympathetic neurons innervating the bovine spleen

Summary The subcellular distribution of noradrenaline (NA), neuropeptide Y (NPY), Met and Leu-enkephalin (ENK), substance P (SP), somatostatin (SOM), and vasoactive intestinal polypeptide (VIP) was investigated in homogenates of bovine splenic nerve. The distribution of noradrenergic peptide-containing nerves in the bovine celiac ganglion, splenic nerve and terminal areas in spleen was studied by indirect immunofluorescence histochemistry using antisera to tyrosine hydroxylase (TH), dopamine--hydroxylase (DBH), NPY, enkephalin peptides, SP, SOM, VIP and peptide HI (PHI).After density gradient centrifugation, high levels of NPY and ENK-like immunoreactivity (LI) were found in high-density gradient fractions, coinciding with the main NA peak. SP, SOM and VIP were found in fractions with a lower density, VIP being also enriched in a heavy fraction; the latter three peptides were present in low concentrations.Immunohistochemistry revealed that staining for NPYLI and ENK-LI partly overlapped that for TH and DBH in celiac ganglia, splenic nerve axons and terminal areas of spleen. Almost all principal ganglion cells were TH- and DBH-immunoreactive. Many were also NPY-immunoreactive, whereas a smaller number were ENK-positive. In the celiac ganglion patches of dense SP-positive networks and some VIP/PHI- and ENK-immunoreactive fibers were seen around cell bodies.The results indicate that NPY and ENK are stored with NA in large dense-cored vesicles in unmyelinated axons of bovine splenic nerve. SP, SOM and VIP appear in different organelles in axon populations separate from sympathetic noradrenergic nerves.     

Changes in expression of the neuropeptide Y Y1 receptor gene in the medial amygdala of transgenic mice during pregnancy and after delivery

Long-term administration of progesterone or allopregnanolone was previously shown to increase Y1 receptor gene expression in the medial amygdala of Y1R/LacZ transgenic mice, which harbor a construct comprising the murine Y1 receptor gene promoter and a lacZ reporter. We have now investigated the effects of physiological fluctuations in the cerebrocortical concentrations of neuroactive steroids during pregnancy on Y1R/LacZ transgene expression by quantitative histochemical analysis of beta-galactosidase activity. Cerebrocortical concentrations of progesterone and its metabolites allopregnanolone and allotetrahydrodeoxycorticosterone were increased on day 18 of pregnancy and had returned to control values 2 days after delivery. Transgene expression in the medial amygdala was also increased on day 18 of pregnancy and had returned to control values 2 days after delivery. Similar results were obtained after analysis of Y1R mRNA levels in the medial amygdala of pregnant mice by in situ hybridization. Administration of the 5alpha-reductase inhibitor finasteride to pregnant mice prevented both the increase in the cerebrocortical concentrations of neuroactive steroids as well as the increase in transgene expression. These data suggest that fluctuations in the brain concentrations of endogenous neuroactive steroids during pregnancy are associated with changes in Y1 receptor gene expression in the medial amygdala, further supporting a functional interaction between the GABAergic and NPY-Y1 receptor systems.